Dr. Reddy's Laboratories
has settled a patent lawsuit with
regarding a generic version of Imitrex.
The terms of the settlement allow Dr. Reddy's to exclusively distribute an authorized generic version of Imitrex at three strengths in the U.S. The expected launch date is the fourth quarter of 2008.
Additional terms of the settlement agreement weren't disclosed. Glaxo's Imitrex is used to treat migraines, and the drug had U.S. sales of $890 million for the 12 months ended last June.